GH Research
GHRS
Market cap $673M

10.85 USD

-0.50

4.41%

Updated Mar 13, 1:52 PM EDT

1 day

-4.41%

5 days

-1.27%

1 month

-24.18%

3 months

40.18%

6 months

30.72%

Year to date

37.17%

1 year

5.34%

5 years

-43.64%

10 years

-43.64%

About: GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Employees: 50

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 7,372 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

780% more call options, than puts

Call options by funds: $88K | Put options by funds: $10K

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

7% more funds holding

Funds holding: 28 [Q3] → 30 (+2) [Q4]

5% more capital invested

Capital invested by funds: $204M [Q3] → $215M (+$10.7M) [Q4]

0.34% more ownership

Funds ownership: 58.66% [Q3] → 59.0% (+0.34%) [Q4]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$14

29%

upside

Avg. target

$30

175%

upside

High target

$40

269%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Guggenheim Eddie Hickman 20% 1-year accuracy 1 / 5 met price target	195%upside $32	Buy Initiated	13 Mar 2025
RBC Capital Brian Abrahams 15% 1-year accuracy 11 / 71 met price target	186%upside $31	Outperform Initiated	7 Mar 2025
Stifel Paul Matteis 25% 1-year accuracy 4 / 16 met price target	195%upside $32	Buy Maintained	27 Feb 2025
Cantor Fitzgerald Charles Duncan 45% 1-year accuracy 31 / 69 met price target	29%upside $14	Overweight Initiated	13 Feb 2025
HC Wainwright & Co. Patrick Trucchio 23% 1-year accuracy 42 / 185 met price target	269%upside $40	Buy Reiterated	27 Jan 2025

See Analyst Rankings

Financial journalist opinion

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Full response to the IND hold on track for submission in mid-2025 Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024 Net cash proceeds of an additional $139.8 million from public offering received in February 2025 DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2024, and provided updates on its business. Business Updates GH001 in Patients with TRD GH001, our proprietary inhalable mebufotenin product candidate, is currently being investigated in a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial in approximately 80 patients with treatment-resistant depression (TRD) (GH001-TRD-201).

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

Zacks Investment Research

GHRS Stock Rallies 55% in a Week: Here's What You Should Know

GH Research stock soars 55% in a week after the company meets the primary goal in a mid-stage depression study of its lead candidate, GH001.

GHRS Stock Rallies 55% in a Week: Here's What You Should Know

GH Research Announces Pricing of $150 Million Public Offering

DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of its previously announced underwritten public offering in the United States of 10,000,000 ordinary shares at a public offering price of $15.00 per share for total gross proceeds of approximately $150 million. All of the ordinary shares are being offered by GH Research PLC. The offering is expected to close on February 6, 2025, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 ordinary shares at the public offering price, less underwriting discounts and commissions.

GH Research Announces Pricing of $150 Million Public Offering

GH Research Announces Proposed Public Offering

DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the commencement of an underwritten public offering in the United States of $150 million of ordinary shares. All of the ordinary shares are to be offered by GH Research PLC. In addition, GH Research PLC intends to grant the underwriters an option to purchase up to an additional $22.5 million of ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

GH Research Announces Proposed Public Offering

Why Is GH Research Stock Trading Higher On Monday?

On Monday, GH Research PLC GHRS said its Phase 2b trial with GH001, an inhalable bufotenin product candidate for treatment-resistant depression, met its primary endpoint.

Why Is GH Research Stock Trading Higher On Monday?

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company, today reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression (TRD) (GH001-TRD-201). GH Research will host a conference call and live webcast today at 8.00 a.m. EST. To register for the event, please click here.

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD).

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

DUBLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates on its business and highlighted key upcoming milestones.

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

Zacks Investment Research

Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?

The mean of analysts' price targets for GH Research (GHRS) points to a 225.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

DUBLIN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2024, and provided updates on its business.

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

See News Rankings

Charts implemented using Lightweight Charts™